TCL Archive Tesetaxel Showed 20 Percent Response In Second-Line Therapy In Phase IIb Trial January 27, 2012
TCL Archive FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint. July 21, 2006
TCL Archive In Brief: FY 1985 Budget Breakdown; Control Gets $64 Million, Construction $6.5; W. VA. $4.5 Maybe November 9, 1984